The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations - PubMed
6 hours ago
- #tumor mosaicism
- #drug combinations
- #KRAS inhibitors
- The GENEVA platform models tumor mosaicism to study variations in responses to KRAS inhibitors and identify better drug combinations.
- GENEVA combines multiple patient-derived and cancer cell lines into pooled 3D cultures and xenografts to study drug responses across diverse genetic backgrounds.
- Key findings include mitochondrial activation driving cell death after KRAS inhibition and epithelial-to-mesenchymal transition as a resistance mechanism.
- GENEVA aims to bridge the gap between preclinical models and patient outcomes by identifying therapeutic targets and optimizing combination therapies.
- Funding sources include UC San Francisco and the National Institutes of Health (NIH).